New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Resilience factors were associated with less severe positive and negative schizophrenia symptoms, suggesting resilience may play a protective role.

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

The Good Side of Bad. I clicked the link and viewed the trailer. It tells the story of three siblings, one of whom is struck by visions of hooded men and psychiatric treatment. I've seen portrayals of ...